A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
← catalyst calendarNCT07765888 · readout in 558 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
375estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-14 | estimated | When the study began enrolling |
| Primary completion | 2028-02-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Tilrekimig — also filed as PF-07275315
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFDifference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placebo
measured Week 16
Difference in the proportion of Validated Investigator Global Assessment (vIGA)-AD™ 0/1 responders between tilrekimig versus placebo
measured Week 16
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed